Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM. Goodman GE, et al. Among authors: beck tm. J Clin Oncol. 1990 Jan;8(1):39-47. doi: 10.1200/JCO.1990.8.1.39. J Clin Oncol. 1990. PMID: 2153194 Clinical Trial.
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Borson R, et al. Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004. Clin Breast Cancer. 2012. PMID: 23040000 Clinical Trial.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. Patel JD, et al. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145346 Free PMC article. Clinical Trial.
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Krill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, Tai F, Marciniak MD, Obasaju C, Hainsworth J. Brufsky A, et al. Clin Breast Cancer. 2011 Aug;11(4):211-20. doi: 10.1016/j.clbc.2011.03.019. Epub 2011 Jul 1. Clin Breast Cancer. 2011. PMID: 21723792 Clinical Trial.
Kidney Health Monitoring in Neonatal Intensive Care Unit Graduates: A Modified Delphi Consensus Statement.
Starr MC, Harer MW, Steflik HJ, Gorga S, Ambalavanan N, Beck TM, Chaudhry PM, Chmielewski JL, Defreitas MJ, Fuhrman DY, Hanna M, Joseph C, Kwiatkowski DM, Krawczeski CD, Liberio BM, Menon S, Mohamed TH, Rumpel JA, Sanderson KR, Schuh MP, Segar JL, Slagle CL, Soranno DE, Vuong KT, Charlton JR, Gist KM, Askenazi DJ, Selewski DT; Neonatal Kidney Health Consensus Workshop. Starr MC, et al. Among authors: beck tm. JAMA Netw Open. 2024 Sep 3;7(9):e2435043. doi: 10.1001/jamanetworkopen.2024.35043. JAMA Netw Open. 2024. PMID: 39269711 Free article.
The 2024 Europe report of the Lancet Countdown on health and climate change: unprecedented warming demands unprecedented action.
van Daalen KR, Tonne C, Semenza JC, Rocklöv J, Markandya A, Dasandi N, Jankin S, Achebak H, Ballester J, Bechara H, Beck TM, Callaghan MW, Carvalho BM, Chambers J, Pradas MC, Courtenay O, Dasgupta S, Eckelman MJ, Farooq Z, Fransson P, Gallo E, Gasparyan O, Gonzalez-Reviriego N, Hamilton I, Hänninen R, Hatfield C, He K, Kazmierczak A, Kendrovski V, Kennard H, Kiesewetter G, Kouznetsov R, Kriit HK, Llabrés-Brustenga A, Lloyd SJ, Batista ML, Maia C, Martinez-Urtaza J, Mi Z, Milà C, Minx JC, Nieuwenhuijsen M, Palamarchuk J, Pantera DK, Quijal-Zamorano M, Rafaj P, Robinson EJZ, Sánchez-Valdivia N, Scamman D, Schmoll O, Sewe MO, Sherman JD, Singh P, Sirotkina E, Sjödin H, Sofiev M, Solaraju-Murali B, Springmann M, Treskova M, Triñanes J, Vanuytrecht E, Wagner F, Walawender M, Warnecke L, Zhang R, Romanello M, Antó JM, Nilsson M, Lowe R. van Daalen KR, et al. Among authors: beck tm. Lancet Public Health. 2024 Jul;9(7):e495-e522. doi: 10.1016/S2468-2667(24)00055-0. Epub 2024 May 12. Lancet Public Health. 2024. PMID: 38749451 Free PMC article. Review. No abstract available.
45 results